A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the ...

Droplet digital PCR measurements of ctDNA may accurately identify patients with melanoma who are at high risk of recurrence. Patients who were ctDNA positive had worse recurrence-free and overall ...

SAN ANTONIO — The randomized phase 3 ZEST trial, which was aimed at evaluating niraparib (Zejula) for prevention or delay of breast cancer recurrence in patients with minimal residual disease (MRD) ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

For patients with liver cancer, a transplant is often the only option. Yet in about 15 to 40% of cases, depending on cancer subtype, the disease returns within five years. If it does, the prognosis is ...

Personalis, Inc. (NASDAQ:PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can accurately identify triple negative breast cancer (TNBC) patients at high risk of ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

CHARLOTTE, N.C. — Circulating tumor DNA (ctDNA) from patients with gastrointestinal (GI) cancers can reflect treatment response, spare some additional treatment, or signal potential remission in those ...

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease At the CURE Educated Patient Breast Cancer Summit, held during ...

ST. PAUL, Minn., April 15 (UPI) --New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether some stage III melanoma patients are likely ...